NO330924B1 - Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode. - Google Patents

Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.

Info

Publication number
NO330924B1
NO330924B1 NO20022836A NO20022836A NO330924B1 NO 330924 B1 NO330924 B1 NO 330924B1 NO 20022836 A NO20022836 A NO 20022836A NO 20022836 A NO20022836 A NO 20022836A NO 330924 B1 NO330924 B1 NO 330924B1
Authority
NO
Norway
Prior art keywords
immunoconjugate
antibody
antibody fragment
diagnosis
metastasis
Prior art date
Application number
NO20022836A
Other languages
English (en)
Other versions
NO20022836L (no
NO20022836D0 (no
Inventor
Richard Harkins
Deborah Parkes
Gordon Parry
Douglas W Schneider
Renate Steinbrecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20022836D0 publication Critical patent/NO20022836D0/no
Publication of NO20022836L publication Critical patent/NO20022836L/no
Publication of NO330924B1 publication Critical patent/NO330924B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20022836A 1999-12-16 2002-06-14 Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode. NO330924B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17237099P 1999-12-16 1999-12-16
US09/732,357 US6682902B2 (en) 1999-12-16 2000-12-07 DNA encoding a novel RG1 polypeptide
PCT/US2000/033901 WO2001044291A2 (en) 1999-12-16 2000-12-15 Polynucleotid encoding the rg1 polypeptide

Publications (3)

Publication Number Publication Date
NO20022836D0 NO20022836D0 (no) 2002-06-14
NO20022836L NO20022836L (no) 2002-08-15
NO330924B1 true NO330924B1 (no) 2011-08-22

Family

ID=26868022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022836A NO330924B1 (no) 1999-12-16 2002-06-14 Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.

Country Status (32)

Country Link
US (5) US6682902B2 (no)
EP (2) EP2048157B1 (no)
JP (1) JP4979867B2 (no)
KR (1) KR100752434B1 (no)
CN (1) CN1297566C (no)
AT (1) ATE440862T1 (no)
AU (1) AU784674B2 (no)
BG (1) BG65898B1 (no)
BR (1) BR0017022A (no)
CA (1) CA2394574A1 (no)
CZ (1) CZ299232B6 (no)
DE (1) DE60042836D1 (no)
DK (1) DK1237915T3 (no)
EE (1) EE05293B1 (no)
ES (1) ES2331106T3 (no)
HR (1) HRP20020549B1 (no)
HU (1) HU229001B1 (no)
IL (2) IL150115A0 (no)
LT (1) LT5046B (no)
ME (1) MEP37808A (no)
MX (1) MXPA02005914A (no)
NO (1) NO330924B1 (no)
NZ (1) NZ519598A (no)
PL (1) PL207634B1 (no)
PT (1) PT1237915E (no)
RO (1) RO122543B1 (no)
RS (1) RS50831B (no)
RU (1) RU2283130C2 (no)
SI (2) SI1237915T1 (no)
SK (2) SK286384B6 (no)
WO (1) WO2001044291A2 (no)
ZA (1) ZA200205638B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528700A (en) * 1998-04-08 2005-02-25 Genentech Inc Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US20070031901A1 (en) * 1999-03-08 2007-02-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
UY28424A1 (es) * 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
CA2707443A1 (en) * 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Conjugates of anti-rg-1 antibodies
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN102346184B (zh) * 2010-08-03 2014-03-26 中国人民解放军军事医学科学院生物工程研究所 Spon2的新用途
DE102012016127A1 (de) 2011-08-31 2013-02-28 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993023057A1 (en) 1992-05-14 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting cancer development
US5871969A (en) 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6177244B1 (en) 1996-05-10 2001-01-23 Beth Israel Deaconess Medical Center Inc. NPG-1 gene that is differentially expressed in prostate tumors
US5804382A (en) 1996-05-10 1998-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for identifying differentially expressed genes and differences between genomic nucleic acid sequences
US6287777B1 (en) 1996-05-10 2001-09-11 Beth Israel Deaconess Medical Center NPG-1 gene that is differentially expressed in prostate tumors
JP3494529B2 (ja) * 1996-06-06 2004-02-09 Ｙｋｋ株式会社 一体成形面ファスナー
WO1998008381A1 (en) * 1996-08-26 1998-03-05 University Of Washington Therapeutic and diagnostic applications of perlecan domain i splice variants
AU6961398A (en) 1997-04-10 1998-10-30 Zymogenetics Inc. Secreted f-spondin homologs
CN1268178A (zh) * 1997-05-06 2000-09-27 人体基因组科学有限公司 粪肠球菌多核苷酸和多肽
EP0986400A4 (en) 1997-05-09 2002-10-09 Smithkline Beecham Corp INTEGRIN LIGAND, HUMAN MINDIN
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
WO2000023108A1 (en) 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6960433B1 (en) * 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide

Also Published As

Publication number Publication date
CA2394574A1 (en) 2001-06-21
HRP20020549B1 (hr) 2013-09-30
RO122543B1 (ro) 2009-08-28
HUP0204224A3 (en) 2004-12-28
PT1237915E (pt) 2009-11-04
RS50831B (sr) 2010-08-31
US20090292112A1 (en) 2009-11-26
EP1237915B1 (en) 2009-08-26
EE05293B1 (et) 2010-04-15
KR20020065575A (ko) 2002-08-13
WO2001044291A3 (en) 2002-01-17
US7307154B2 (en) 2007-12-11
HU229001B1 (en) 2013-07-29
RU2283130C2 (ru) 2006-09-10
LT2002070A (en) 2003-04-25
NO20022836L (no) 2002-08-15
US6682902B2 (en) 2004-01-27
MXPA02005914A (es) 2003-02-27
US20040152139A1 (en) 2004-08-05
ZA200205638B (en) 2003-10-15
SK8482002A3 (en) 2003-02-04
WO2001044291A2 (en) 2001-06-21
SK288147B6 (sk) 2013-12-02
BG65898B1 (bg) 2010-04-30
JP2003521244A (ja) 2003-07-15
US7893217B2 (en) 2011-02-22
SK286384B6 (sk) 2008-08-05
AU3074601A (en) 2001-06-25
JP4979867B2 (ja) 2012-07-18
CN1434832A (zh) 2003-08-06
PL207634B1 (pl) 2011-01-31
ES2331106T3 (es) 2009-12-22
EP2048157A1 (en) 2009-04-15
US20020004047A1 (en) 2002-01-10
SI1237915T1 (sl) 2009-12-31
EP2048157B1 (en) 2012-10-10
KR100752434B1 (ko) 2007-08-27
ATE440862T1 (de) 2009-09-15
RU2002119208A (ru) 2004-02-27
LT5046B (lt) 2003-08-25
YU44602A (sh) 2005-06-10
US7887804B2 (en) 2011-02-15
CZ299232B6 (cs) 2008-05-21
DE60042836D1 (de) 2009-10-08
US20090214422A1 (en) 2009-08-27
DK1237915T3 (da) 2009-11-16
CN1297566C (zh) 2007-01-31
NZ519598A (en) 2004-03-26
BR0017022A (pt) 2002-11-05
HRP20020549A2 (en) 2004-04-30
MEP37808A (en) 2011-05-10
AU784674B2 (en) 2006-05-25
HUP0204224A2 (hu) 2003-03-28
SI21140A (sl) 2003-08-31
EP1237915A2 (en) 2002-09-11
EE200200323A (et) 2003-10-15
BG106823A (bg) 2003-04-30
NO20022836D0 (no) 2002-06-14
US20040023307A1 (en) 2004-02-05
IL150115A (en) 2013-11-28
PL356220A1 (en) 2004-06-28
IL150115A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
NO330924B1 (no) Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
ATE420175T1 (de) C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
WO2002010382A3 (en) Trp8, trp9 and trp10, markers for cancer
ATE541052T1 (de) Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon
BR0308953A (pt) composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
ATE354656T1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
ATE252374T1 (de) Eingekapselte antikörper-produzierende zellen
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
WO2001081577A3 (en) Dna encoding the prost 03 polypeptide
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2002066506A3 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
IL210928A0 (en) Antibodies specific for 238p1b2 and uses thereof
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001075016A3 (fr) Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide
WO2001094540A3 (fr) Nouveau polypeptide, glycosyl hydrolase humaine 23, et polynucleotide codant ce polypeptide
WO2001075033A3 (en) A novel polypeptide, a human cell division cycle regulatory protein 9 and the polynucleotide encoding the polypeptide
WO2001083685A3 (fr) Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide
WO2001079431A3 (fr) Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees